The type 1 CALR mutation shows a significantly higher risk of transformation to myelofibrosis in ET, and patients with both CALR types show a higher platelet count, lower hemoglobin and leukocyte values in comparison to JAK2-positive ET [131,132]. This evidence concerns the gene JAK2 and essential thrombocythemia.